Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Mallinckrodt
Teva
UBS
US Department of Justice
Queensland Health

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,414,921

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,414,921 protect, and when does it expire?

Patent 8,414,921 protects JANUMET and is included in one NDA.

This patent has nine patent family members in six countries.

Summary for Patent: 8,414,921
Title:Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Abstract: Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
Inventor(s): Kamali; Ashkan (West Conshohocken, PA), Alani; Laman (Lansdale, PA), Fliszar; Kyle A. (Quakertown, PA), Ghosh; Soumojeet (Lansdale, PA), Tijerina; Monica (Doylestown, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/085,722
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,414,921
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Formulation;

Drugs Protected by US Patent 8,414,921

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme JANUMET metformin hydrochloride; sitagliptin phosphate TABLET;ORAL 022044-002 Mar 30, 2007 RX Yes Yes   Try a Free Trial   Try a Free Trial Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN   Try a Free Trial
Merck Sharp Dohme JANUMET metformin hydrochloride; sitagliptin phosphate TABLET;ORAL 022044-001 Mar 30, 2007 RX Yes No   Try a Free Trial   Try a Free Trial Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,414,921

PCT Information
PCT FiledDecember 12, 2006PCT Application Number:PCT/US2006/047380
PCT Publication Date:July 12, 2007PCT Publication Number: WO2007/078726

International Family Members for US Patent 8,414,921

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006333151   Try a Free Trial
Canada 2633167   Try a Free Trial
China 101365432   Try a Free Trial
European Patent Office 1962827   Try a Free Trial
Japan 2009519934   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cantor Fitzgerald
QuintilesIMS
Farmers Insurance
Fuji
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.